시장보고서
상품코드
1422774

세계의 차세대 시퀀싱 시장 : 제품별, 시퀀싱 유형별, 기술별, 용도별, 최종사용자별, 지역별, 기회 및 예측(2017-2031년)

Next-Generation Sequencing Market Assessment, By Product, By Sequencing Type, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

발행일: | 리서치사: Market Xcel - Markets and Data | 페이지 정보: 영문 223 Pages | 배송안내 : 3-5일 (영업일 기준)

■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

세계 차세대 시퀀싱 시장 규모는 2024-2031년의 예측 기간 동안 17.52%의 연평균 복합 성장률(CAGR)로 2023년 105억 9,000만 달러에서 2031년 385억 2,000만 달러로 성장할 것으로 예상됩니다. 세계 차세대 시퀀싱 시장의 성장과 확장을 촉진하는 다양한 요인이 있습니다. 주요 요인으로는 비용 절감, 임상 진단 분야에서의 사용 확대, 기술 발전, 연구 활동 확대, 공동 파트너십, 농업 및 동물 게놈 분야에서의 광범위한 활용, 개인 맞춤형 의료에 대한 수요 증가, 정부 지원 이니셔티브 및 자금 지원, NGS 기술에 대한 인식 및 수용성 증가 등이 있습니다. 등이 있습니다.

이에 따라 시퀀싱 비용의 지속적인 감소로 인해 연구자와 임상의가 다양한 분야에서 NGS를 사용할 수 있게 되어 그 활용도가 크게 확대되었습니다. 동시에 임상 진단에서 NGS의 급격한 증가는 질병 식별, 치료 계획 및 맞춤형 의료 분야에서 그 능력을 활용하여 의료 분야에서 NGS의 중요성을 높이는 변화를 가져오고 있습니다. 시퀀싱 기술 발전의 초석은 지속적으로 정확성, 속도, 비용 효율성을 향상시킴으로써 다양한 산업 분야에서 NGS의 매력을 높이고 세계 차세대 시퀀싱 시장의 성장을 가속하고 있습니다. 이러한 모멘텀은 학계, 제약 및 생명공학 연구 사업의 급증으로 더욱 가속화되어 유전체학 및 그 실용적 응용에 대한 더 깊은 탐구를 가능하게 하고 있습니다.

세계 차세대 시퀀싱 시장에서의 시너지 협력과 파트너십은 기술 혁신을 촉진하고, 제품 강화를 촉진하며, NGS 용도의 스펙트럼을 넓히고 있습니다. 또한, 농업 및 동물 유전체학에 NGS를 통합함으로써 작물 개량, 육종 프로그램 및 질병 분석과 관련된 관행에 혁명을 가져왔으며, 그 유용성은 인간 건강 관리 분야로까지 확대되고 있습니다. 개인 맞춤형 의료에 대한 수요 증가는 맞춤형 치료를 위해 개별 유전적 변이를 해독하는 NGS의 능력을 활용하는 데 있어 매우 중요한 원동력으로 작용하고 있습니다. 정부의 적극적인 노력과 재정적 지원은 NGS 기술의 연구, 발전 및 광범위한 채택을 촉진하고 있습니다. 결국 NGS에 대한 과학계와 일반 대중의 인식과 수용도가 높아짐에 따라 NGS의 중요성이 높아지고 있으며, 전 세계 차세대 시퀀싱 시장 전반에서 혁신과 발전에 필수적인 장비로서 매우 중요한 역할을 확고히 하고 있습니다.

이 보고서는 세계 차세대 시퀀싱 시장에 대해 조사했으며, 시장 개요와 함께 제품별/시퀀싱 유형별/기술별/용도별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 조사 방법

제2장 프로젝트의 범위와 정의

제3장 주요 요약

제4장 세계의 차세대 시퀀싱 시장 전망, 2017년-2031년

  • 시장 규모와 예측
  • 제품별
  • 시퀀싱 유형별
  • 기술별
  • 용도별
  • 최종사용자별
  • 지역별
  • 기업별 시장 점유율(%), 2023년

제5장 세계의 차세대 시퀀싱 시장 전망, 지역별, 2017년-2031년

  • 북미
  • 유럽
  • 남미
  • 아시아태평양
  • 중동 및 아프리카

제6장 시장 매핑, 2023년

제7장 거시환경과 산업 구조

  • 수급 분석
  • 수출입 분석
  • 밸류체인 분석
  • PESTEL 분석
  • Porter의 Five Forces 분석

제8장 시장 역학

제9장 규제 프레임워크와 혁신

제10장 주요 시장 진출기업 상황

제11장 가격 분석

제12장 사례 연구

제13장 주요 기업 전망

  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Group
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Macrogen, Inc.
  • Pacific Biosciences of California, Inc.
  • Genewiz, LLC
  • 10x Genomics, Inc.
  • Oxford Nanopore Technologies plc
  • F. Hoffmann-La Roche AG

제14장 전략적 제안

제15장 문의와 면책사항

LSH 24.02.21

Global next-generation sequencing market is projected to witness a CAGR of 17.52% during the forecast period 2024-2031, growing from USD 10.59 billion in 2023 to USD 38.52 billion in 2031. Various elements have propelled the growth and expansion of the global next-generation sequencing market. Key factors encompass the reduction in costs, increased applications in clinical diagnostics, advancements in technology, expanding research activities, collaborative partnerships, broader uses in agriculture and animal genomics, rising demand for personalized medicine, supportive government initiatives and funding, and the escalating awareness and acceptance of NGS technologies.

In line with this, the continual decrease in sequencing expenses has notably broadened accessibility, allowing researchers and clinicians to utilize NGS across various disciplines. Simultaneously, the upsurge in NGS applications in clinical diagnostics has been transformative, harnessing its capabilities for disease identification, treatment planning, and the realm of personalized medicine, consequently enhancing its importance in healthcare. The cornerstone of advancements in sequencing technologies has consistently improved precision, speed, and cost-effectiveness, thereby increasing NGS's appeal across diverse industries and propelling the growth of global next-generation sequencing market. This momentum has been further driven by the proliferation of academic, pharmaceutical, and biotechnological research undertakings, enabling a more profound exploration of genomics and its practical applications.

Synergistic collaborations and partnerships within the global next-generation sequencing market have spurred innovation, propelling product enhancements and broadening the spectrum of NGS applications. Furthermore, the integration of NGS in agricultural and animal genomics has revolutionized practices related to crop enhancement, breeding programs, and disease analysis, extending its utility beyond human healthcare. The escalating demand for personalized medicine has emerged as a pivotal driver, harnessing NGS's capability to decipher individual genetic variations for tailor-made treatments. Supportive government initiatives and funding have incentivized research, advancement, and the widespread adoption of NGS technologies. Ultimately, the growing awareness and acceptance of NGS within the scientific community and among the general population have bolstered its significance, solidifying its pivotal role as an indispensable instrument for innovation and progress across the global next-generation sequencing market.

Increased Applications in Clinical Diagnostics

The significant increase in clinical diagnostics applications serves as a fundamental driver advancing the global next-generation sequencing market. This surge originates from NGS's transformative capabilities in identifying diseases, predicting their progression, and tailoring treatment plans. Through comprehensive genomic profiling, NGS aids in detecting disease-related genetic variations, improving diagnostic accuracy and refining treatment decisions. Its versatility spans across oncology, inherited conditions, infectious diseases, and pharmacogenomics, offering in-depth insights into individual genetic profiles. Furthermore, the ongoing enhancement of NGS technologies has diminished expenses and enhanced effectiveness, rendering it more feasible for regular clinical utilization. Consequently, the incorporation of NGS into clinical routines is expanding, catalysing a shift towards precision medicine. This amplified adoption in clinical environments not only elevates patient care standards but also propels the upward trajectory of the global NGS market, emphasizing its substantial impact on contemporary healthcare practices.

Technological Advancements

Technological advancements, notably Artificial Intelligence (AI), are potent catalysts propelling the global next-generation sequencing market forward. AI integration augments NGS by streamlining data analysis, enhancing accuracy, and expediting insights from complex genomic information. Machine learning algorithms assist in interpreting vast sequencing datasets, facilitating the identification of genetic patterns linked to diseases or therapeutic responses. This convergence of AI with NGS amplifies efficiency, reduces costs, and enables innovative applications, extending the technology's appeal across research, clinical diagnostics, and personalized medicine. Such advancements are pivotal in shaping the landscape of genomics and its widespread utilization, underscoring AI's crucial role in advancing the NGS domain.

For instance, in July 2023, South Korea's NGeneBio Co., a medical diagnostics firm, revealed the creation of "NGeneBioAI," an AI-driven precision diagnostic company in the United States. Fully financed by its parent company, NGeneBio, this venture is poised to significantly impact the US cancer diagnostics market. Leveraging its next-generation sequencing (NGS) precision diagnostic platform, NGeneBioAI aims to establish a pivotal presence in the realm of cancer diagnostics within the United States.

Government Initiatives

Governments across the globe are employing varied approaches, notably promoting collaborations between the public and private sectors, to strengthen the global next-generation sequencing market. These strategies aim to merge governmental resources with the expertise of private entities, fostering cooperation in technological advancements, genomics research, and innovative practices. Through these partnerships, governments facilitate knowledge exchange, funding accessibility and the establishment of supportive structures, hastening the uptake and advancement of NGS technologies. These coordinated endeavors leverage the strengths of both sectors, driving the expansion of the NGS market and securing its pivotal role in propelling worldwide scientific advancements and progress in healthcare.

For instance, in October 2023, The Department of Health and Human Services disclosed awards exceeding USD 500 million to aid companies advancing their vaccine candidates into Phase 2b clinical trials and innovating new technologies within Project NextGen. This initiative, a USD 5 billion government endeavour, aims to accelerate the development of next-gen vaccines and treatments via collaborations between public and private entities. The funding supports efforts to expedite vaccine development and the exploration of cutting-edge technologies, reflecting Project NextGen's commitment to catalysing advancements in the medical field through strategic partnerships.

Growing Demand for RNA Sequencing Tools

The surging desire for RNA sequencing tools is crucial in propelling the global next-generation sequencing market. This increased requirement stems from the pivotal function of RNA sequencing in interpreting gene expression, investigating transcriptomic patterns, and comprehending RNA-based mechanisms within health and disease contexts. RNA sequencing empowers the examination of various RNA molecules, enabling the elucidation of complex biological processes, discovery of biomarkers, and identification of therapeutic targets. As the scientific community increasingly acknowledges RNA's importance, the rising demand for RNA sequencing tools drives innovation in NGS technologies, significantly contributing to market expansion and advancing biological research and clinical applications.

As an example, in May 2023, Twist Bioscience Corporation-a business that empowers clients to thrive by providing premium synthetic DNA via its silicon platform-announced the introduction of a range of RNA sequencing instruments, comprising the Twist RNA Exome, Twist RNA Library Prep Kit, and the Twist Ribosomal RNA (rRNA) & Haemoglobin (Globin) Depletion Kit, in addition to customized target enrichment capabilities for RNA and whole transcriptome sequencing.

Growing Popularity of Next-Generation Sequencing Service

The increasing need for advanced sequencing services drives the global next-generation sequencing market. NGS transforms genomics, facilitating swift, cost-efficient DNA sequencing. Its wide-ranging applications in healthcare, agriculture, and research propel market growth. Heightened occurrences of genetic disorders, personalized medicine trends, and bioinformatics advancements boost NGS demand. Moreover, reduced sequencing expenses enhance its accessibility. Industries and research bodies increasingly embrace NGS due to its high-throughput capabilities and precise data, fostering market expansion. This surge in demand sustains the continual upward trajectory of the global next generation sequencing market, meeting the diverse needs across various fields seeking comprehensive genomic insights.

For instance, in August 2023, Quantum-Si, a company specializing in protein sequencing, introduced a groundbreaking Next-Generation Protein Sequencing Platform. This innovative Platinum platform, the first of its kind, offers a straightforward, user-friendly benchtop solution that seamlessly fits into current workflows. It aims to enable laboratories worldwide to perform benchtop proteomics experiments easily and effectively.

Future Market Scenario (2024-2031F)

The future of the global next-generation sequencing market holds immense promise, driven by technological progress like enhanced automation, precision, and cost reduction. NGS's adaptability spans diverse domains like healthcare, agriculture, and scientific research, amplifying its importance. Rising genetic-based treatments and diagnostics, alongside a surging demand for personalized medicine, heighten NGS's relevance in healthcare. Moreover, its application in agricultural genomics signals potential for improved crop productivity and sustainability.

Ongoing innovations in bioinformatics and data analysis refine NGS capabilities, uncovering deeper genetic insights. Advancements toward point-of-care sequencing and potential integration with AI foreshadow a future of more accessible and efficient genomic analysis. Despite challenges like data management and ethical concerns, persistent research, partnerships, and regulatory backing maintain an optimistic market trajectory. Consequently, the global NGS market appears poised for sustained growth and transformative advancements, reflecting a bright and promising future.

Key Players Landscape and Outlook

Major entities in the global next-generation sequencing market actively seek partnerships to stimulate innovation and industry expansion. These alliances facilitate the exchange of resources, merging expertise and capitalizing on complementary strengths to pioneer advanced technologies and remedies. Collaborations among leading NGS firms bolster research capacities, hasten product advancement, and enhance market reach. Through combined resources, risk-sharing, and diverse viewpoints, these partnerships target intricate issues, elevate product portfolios, and establish stronger footholds in the competitive global next-generation sequencing market. Ultimately, they cultivate a more resilient and vibrant market environment, contributing to a dynamic industry ecosystem.

To help increase local access to NGS-based testing for patients with lung and breast cancer in more than 30 countries across Latin America, Africa, the Middle East, and Asia, where advanced genomic testing has previously been limited or unavailable, Pfizer and Thermo Fisher Scientific Inc. announced in May 2023 that they had entered into a collaboration agreement.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Next-Generation Sequencing Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Product
    • 4.2.1. NGS Consumables
    • 4.2.2. Presequencing Products & Services
    • 4.2.3. Sequencing Services
    • 4.2.4. NGS Platforms
    • 4.2.5. Bioinformatics
    • 4.2.6. Services for NGS Platforms
  • 4.3. By Sequencing Type
    • 4.3.1. RNA Sequencing
    • 4.3.2. Whole Genome Sequencing
    • 4.3.3. Whole Exome Sequencing
    • 4.3.4. Targeted Resequencing
    • 4.3.5. CHIP Sequencing
    • 4.3.6. De Novo Sequencing
    • 4.3.7. Methyl Sequencing
    • 4.3.8. Others
  • 4.4. By Technology
    • 4.4.1. Sequencing by Synthesis
    • 4.4.2. Single-Molecule Real-Time Sequencing
    • 4.4.3. Nanopore Sequencing
    • 4.4.4. Ion Semiconductor Sequencing
    • 4.4.5. Others
  • 4.5. By Application
    • 4.5.1. Drug Discovery and Personalized Medicine
    • 4.5.2. Diagnostics
    • 4.5.3. Genetic Screening
    • 4.5.4. Agriculture and Animal Research
    • 4.5.5. Others
  • 4.6. By End-user
    • 4.6.1. Hospitals & Clinics
    • 4.6.2. Academic Institutes & Research Centers
    • 4.6.3. Pharmaceutical & Biotechnology Companies
    • 4.6.4. Others
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. South America
    • 4.7.4. Asia-Pacific
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Next-Generation Sequencing Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Product Type
      • 5.1.2.1. NGS Consumables
      • 5.1.2.2. Presequencing Products & Services
      • 5.1.2.3. Sequencing Services
      • 5.1.2.4. NGS Platforms
      • 5.1.2.5. Bioinformatics
      • 5.1.2.6. Services for NGS Platforms
    • 5.1.3. By Sequencing Type
      • 5.1.3.1. RNA Sequencing
      • 5.1.3.2. Whole Genome Sequencing
      • 5.1.3.3. Whole Exome Sequencing
      • 5.1.3.4. Targeted Resequencing
      • 5.1.3.5. CHIP Sequencing
      • 5.1.3.6. De Novo Sequencing
      • 5.1.3.7. Methyl Sequencing
      • 5.1.3.8. Others
    • 5.1.4. By Technology
      • 5.1.4.1. Sequencing by Synthesis
      • 5.1.4.2. Single-Molecule Real-Time Sequencing
      • 5.1.4.3. Nanopore Sequencing
      • 5.1.4.4. Ion Semiconductor Sequencing
      • 5.1.4.5. Others
    • 5.1.5. By Application
      • 5.1.5.1. Drug Discovery and Personalized Medicine
      • 5.1.5.2. Diagnostics
      • 5.1.5.3. Genetic Screening
      • 5.1.5.4. Agriculture and Animal Research
      • 5.1.5.5. Others
    • 5.1.6. By End-user
      • 5.1.6.1. Hospitals & Clinics
      • 5.1.6.2. Academic Institutes & Research Centers
      • 5.1.6.3. Pharmaceutical & Biotechnology Companies
      • 5.1.6.4. Others
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. Value
      • 5.1.7.1.2. Volume
      • 5.1.7.2. By Product Type
      • 5.1.7.2.1. NGS Consumables
      • 5.1.7.2.2. Presequencing Products & Services
      • 5.1.7.2.3. Sequencing Services
      • 5.1.7.2.4. NGS Platforms
      • 5.1.7.2.5. Bioinformatics
      • 5.1.7.2.6. Services for NGS Platforms
      • 5.1.7.3. By Sequencing Type
      • 5.1.7.3.1. RNA Sequencing
      • 5.1.7.3.2. Whole Genome Sequencing
      • 5.1.7.3.3. Whole Exome Sequencing
      • 5.1.7.3.4. Targeted Resequencing
      • 5.1.7.3.5. CHIP Sequencing
      • 5.1.7.3.6. De Novo Sequencing
      • 5.1.7.3.7. Methyl Sequencing
      • 5.1.7.3.8. Others
      • 5.1.7.4. By Technology
      • 5.1.7.4.1. Sequencing by Synthesis
      • 5.1.7.4.2. Single-Molecule Real-Time Sequencing
      • 5.1.7.4.3. Nanopore Sequencing
      • 5.1.7.4.4. Ion Semiconductor Sequencing
      • 5.1.7.4.5. Others
      • 5.1.7.5. By Application
      • 5.1.7.5.1. Drug Discovery and Personalized Medicine
      • 5.1.7.5.2. Diagnostics
      • 5.1.7.5.3. Genetic Screening
      • 5.1.7.5.4. Agriculture and Animal Research
      • 5.1.7.5.5. Others
      • 5.1.7.6. By End-user
      • 5.1.7.6.1. Hospitals & Clinics
      • 5.1.7.6.2. Academic Institutes & Research Centers
      • 5.1.7.6.3. Pharmaceutical & Biotechnology Companies
      • 5.1.7.6.4. Others
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Sequencing
  • 6.3. By Technology
  • 6.4. By Application
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Illumina Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Thermo Fisher Scientific Inc.
  • 13.3. BGI Group
  • 13.4. Agilent Technologies, Inc.
  • 13.5. Qiagen N.V.
  • 13.6. Macrogen, Inc.
  • 13.7. Pacific Biosciences of California, Inc.
  • 13.8. Genewiz, LLC
  • 13.9. 10x Genomics, Inc.
  • 13.10. Oxford Nanopore Technologies plc
  • 13.11. F. Hoffmann-La Roche AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제